CO60 Real-World Effectiveness of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Population-Based Study in South Korea

Diabetes patients are recommended to maintain their LDL cholesterol below 100mg/dL prevent cardiovascular (CV) events. Therefore, atorvastatin is reimbursed for diabetes having ≥100mg/dL in Korea. We aimed assess the real-world effectiveness of primary prevention CV events type 2 mellitus (T2DM) using population-based database. A retrospective cohort study was conducted National Health Insurance Service Customized data during 2008–2018. Atorvastatin users were defined as T2DM with continuous use 3 months 2009–2012, and no previous or within 1 year. Statin non-users without statin prescriptions 2009–2012 Cancer excluded from both groups. Propensity score matching a 1:1 ratio by patient baseline characteristics. Patients followed up until 2018 ascertain incidence As proportional hazard assumption not met, extended Cox model used heaviside function time (split at years) association between During 6–10 years follow-up, event rates 1.21 1.43 per 100 person-years (n=41,024) (n=41,024), respectively. For composite events, (HR) comparing significant before (0.975; 95% confidence interval [CI], 0.904–1.052), whereas it became after (0.760; CI, 0.719–0.803). HRs lower stroke (0.746; 0.693–0.803) compared coronary heart disease (0.779; 0.716–0.847). associated reduced risk treatment initiation patients.